Continuous infusion of complement by an automated cell processor enhances cytotoxicity of monoclonal antibody sensitized leukemia cells.
We report the use of the Haemonetics cell processor for monoclonal antibody (MoAb) and complement (C')-mediated lysis of leukemia cells. Using the HL-60 promyelocytic leukemia cell line, we can achieve a six-log depletion of HL-60 colony-forming cells in cell mixtures containing 1% HL-60 cells and 99% normal peripheral blood or bone marrow leukocytes at 10(7)/ml after a single 60-min treatment with an anti-myeloid MoAb, PM-81, plus C'. In this procedure, we continuously infuse a solution of fresh C' while removing medium containing spent C'. We have utilized this procedure to purge remission bone marrow from patients with acute myelogenous leukemia in preparation for autologous bone marrow transplantation. There were no adverse effects to normal progenitor cells of the granulocyte, monocyte and erythrocyte lineages as measured in colony-forming assays. Other potential benefits of using the cell processor method of cytotoxicity include reduction in treatment time and the amounts of costly reagents.
Howell
A L
AL
Department of Microbiology, Dartmouth-Hitchcock Medical Center, Hanover, NH.
Fogg-Leach
M
M
Davis
B H
BH
Ball
E D
ED
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001853:Bone Marrow / Q000276:immunology / Q000473:pathology; D016026:Bone Marrow Transplantation; D002469:Cell Separation / Q000379:methods; D003165:Complement System Proteins; D003602:Cytotoxicity, Immunologic; D006801:Humans; D066298:In Vitro Techniques; D007938:Leukemia / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy; D015473:Leukemia, Promyelocytic, Acute / Q000276:immunology / Q000473:pathology / Q000628:therapy; D014182:Transplantation, Autologous; D014407:Tumor Cells, Cultured / Q000276:immunology
D000911:Antibodies, Monoclonal; D003165:Complement System Proteins